Biotech

All Articles

Gilead spends J&ampJ $320M to leave licensing bargain for seladelpar

.Along With Gilead Sciences about to an FDA choice for its liver condition medicine seladelpar, the ...

' All palms on deck' at Lilly as peers target obesity market

.CEO David Ricks can find the providers putting together tents at basecamp behind Eli Lilly in a try...

Entero laying off team, vacating workplace and also pausing R&ampD

.Cushion Liquidators has actually switched Entero Rehabs white colored as a slab. The collector got ...

Exelixis goes down ADC after determining it's no match for Tivdak

.Exelixis is actually losing hope on its cells aspect (TF)- targeting antibody-drug conjugate after ...

Relay dislikes SHP2 prevention after Genentech leaves

.3 weeks after Roche's Genentech unit ignored an SHP2 inhibitor deal, Relay Rehab has actually verif...

Stoke's Dravet syndrome med launched of predisposed scientific hold

.Stoke Therapeutics' Dravet syndrome medicine has actually been actually without a predisposed hold,...

Fierce Biotech's Gabrielle Masson offers Strong 15 at NYSE

.Brutal Biotech Partner Publisher Gabrielle Masson showed the 2024 training class of Brutal 15 champ...

Novo Nordisk centers once-monthly GLP-1\/ GIP agonist, MASH possibility

.Novo Nordisk has actually axed its once-monthly twin GLP-1/ GIP receptor agonist, ending (PDF) grow...

Daiichi pays out Merck $170M to create lung cancer T-cell engager contract

.Merck &amp Co. has actually swiftly gotten back a few of the costs of its own Harp on Rehabs buyout...

BioMarin stops preclinical genetics treatment for heart disease

.After BioMarin administered a spring tidy of its pipeline in April, the company has decided that it...